Published in Nature · View the paper (DOI)
A study from Boston Children's Hospital and Dana-Farber Cancer Institute found that an existing epigenetic drug can increase the effectiveness of chemotherapy for patients with non-small-cell lung cancer (NSCLC) who have BRG1 or EGFR mutations. This breakthrough suggests a new approach to precision medicine in cancer treatment.
Coverage from 2 institutions